Is NAUSEA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed NAUSEA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 165 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported NAUSEA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and NAUSEA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause NAUSEA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes NAUSEA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if NAUSEA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing NAUSEA: 165
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where NAUSEA is a reported side effect: 4.9564%

FDA reports of any drug causing NAUSEA : 196083
Average percentage for all medicated patients where NAUSEA is reported as a complication: 1.2289%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with NAUSEA:

BYETTA (15071 patients)
CHANTIX (13928 patients)
ASPIRIN (12650 patients)
FOSAMAX (7433 patients)
HEPARIN SODIUM INJECTION (7233 patients)
NEXIUM (6749 patients)
METFORMIN HCL (6333 patients)
LIPITOR (6255 patients)
VIOXX (6108 patients)
SYNTHROID (5985 patients)
HUMIRA (5972 patients)
FORTEO (5969 patients)
LISINOPRIL (5903 patients)
PREDNISONE (5277 patients)
LASIX (5032 patients)
CYMBALTA (4911 patients)
XANAX (4610 patients)
SEROQUEL (4533 patients)
ENBREL (4346 patients)
OMEPRAZOLE (4309 patients)
REMICADE (4304 patients)
METHOTREXATE (4200 patients)
PRILOSEC (4108 patients)
PAXIL (4094 patients)
ATENOLOL (4086 patients)
YAZ (4038 patients)
LYRICA (3997 patients)
NEURONTIN (3936 patients)
SIMVASTATIN (3934 patients)
FOLIC ACID (3894 patients)
LANTUS (3887 patients)
HYDROCHLOROTHIAZIDE (3850 patients)
ZOLOFT (3771 patients)
COUMADIN (3684 patients)
ACETAMINOPHEN (3657 patients)
DIGOXIN (3630 patients)
YASMIN (3608 patients)
OXYCONTIN (3574 patients)
AMBIEN (3561 patients)
PROTONIX (3554 patients)
PLAVIX (3541 patients)
FUROSEMIDE (3479 patients)
IBUPROFEN (3449 patients)
LEXAPRO (3310 patients)
ZOMETA (3300 patients)
LEVOTHYROXINE SODIUM (3280 patients)
ZOFRAN (3244 patients)
NORVASC (3238 patients)
ALBUTEROL (3237 patients)
PREVACID (3210 patients)
TOPROL-XL (3177 patients)
TYSABRI (3092 patients)
VITAMIN D (3056 patients)
GLUCOPHAGE (3041 patients)
ZOCOR (3037 patients)
SANDOSTATIN LAR (2915 patients)
ATIVAN (2914 patients)
POTASSIUM CHLORIDE (2880 patients)
VICTOZA (2876 patients)
VICODIN (2872 patients)
LORAZEPAM (2869 patients)
CELEBREX (2852 patients)
CRESTOR (2747 patients)
DURAGESIC-100 (2656 patients)
RIBAVIRIN (2654 patients)
CALCIUM (2650 patients)
CISPLATIN (2633 patients)
PERCOCET (2588 patients)
ACTOS (2504 patients)
DEXAMETHASONE (2417 patients)
GABAPENTIN (2391 patients)
LEVAQUIN (2368 patients)
AVONEX (2337 patients)
ALLOPURINOL (2257 patients)
ADVAIR DISKUS 100/50 (2252 patients)
EFFEXOR (2250 patients)
PROZAC (2249 patients)
PEGASYS (2247 patients)
OXYCODONE HCL (2242 patients)
DIOVAN (2238 patients)
GLEEVEC (2213 patients)
CLONAZEPAM (2158 patients)
PREMARIN (2149 patients)
FLUOROURACIL (2130 patients)
MORPHINE (2110 patients)
CARBOPLATIN (2108 patients)
KLONOPIN (2086 patients)
METFORMIN (2079 patients)
AVANDIA (2072 patients)
GLIPIZIDE (2064 patients)
PREDNISOLONE (2058 patients)
WELLBUTRIN (2051 patients)
METOPROLOL TARTRATE (2045 patients)
PREDNISONE TAB (2038 patients)
AMARYL (2034 patients)
EXJADE (1991 patients)
MULTI-VITAMINS (1990 patients)
ACCUTANE (1983 patients)
AREDIA (1971 patients)
DECADRON (1969 patients)
INSULIN (1953 patients)
ALPRAZOLAM (1952 patients)
WARFARIN SODIUM (1940 patients)
AMLODIPINE (1928 patients)
SINGULAIR (1918 patients)
MULTI-VITAMIN (1902 patients)
EFFEXOR XR (1876 patients)
COREG (1852 patients)
PRISTIQ (1833 patients)
TRAMADOL HCL (1832 patients)
BENADRYL (1825 patients)
COMPAZINE (1821 patients)
HEPARIN SODIUM (1790 patients)
LORTAB (1786 patients)
GLYBURIDE (1785 patients)
ZANTAC (1785 patients)
FENTANYL (1778 patients)
NIASPAN (1772 patients)
ZYRTEC (1726 patients)
XELODA (1725 patients)
MIRENA (1714 patients)
SPIRIVA (1694 patients)
CELEXA (1672 patients)
VALIUM (1667 patients)
REGLAN (1634 patients)
NEXAVAR (1616 patients)
TRAZODONE HCL (1605 patients)
LAMICTAL (1585 patients)
NITROGLYCERIN (1584 patients)
HUMALOG (1577 patients)
CYCLOPHOSPHAMIDE (1576 patients)
DIAZEPAM (1555 patients)
SPIRONOLACTONE (1540 patients)
SOLIRIS (1534 patients)
METOPROLOL (1514 patients)
PROMETHAZINE (1514 patients)
FISH OIL (1493 patients)
VITAMIN B-12 (1492 patients)
TYLENOL (CAPLET) (1479 patients)
TYLENOL (1478 patients)
ZETIA (1461 patients)
AVASTIN (1440 patients)
DILAUDID (1439 patients)
METOCLOPRAMIDE (1431 patients)
ALLEGRA (1420 patients)
ASCORBIC ACID (1408 patients)
PEG-INTRON (1404 patients)
TOPAMAX (1404 patients)
REVLIMID (1395 patients)
COZAAR (1385 patients)
ORTHO EVRA (1381 patients)
RANITIDINE (1366 patients)
AVELOX (1355 patients)
BONIVA (1333 patients)
VALTREX (1315 patients)
ONDANSETRON (1309 patients)
PLAN B ONE-STEP (1300 patients)
LANSOPRAZOLE (1285 patients)
AMOXICILLIN (1282 patients)
FLEXERIL (1280 patients)
CALCIUM CARBONATE (1278 patients)
CAPECITABINE (1275 patients)
COLACE (1269 patients)
REBIF (1259 patients)
OXALIPLATIN (1254 patients)
VITAMIN E (1247 patients)
LEVOXYL (1239 patients)
ACTONEL (1237 patients)
MORPHINE SULFATE (1231 patients)
CLONIDINE (1228 patients)
SUTENT (1223 patients)
PANTOPRAZOLE (1220 patients)
ALTACE (1212 patients)
NAPROXEN (1205 patients)
TAXOL (1197 patients)
NOVOLOG (1197 patients)
CIPROFLOXACIN (1181 patients)
HYDROCODONE (1173 patients)
LOPRESSOR (1160 patients)
STRATTERA (1154 patients)
CITALOPRAM HYDROBROMIDE (1150 patients)
PHENERGAN (1146 patients)
FLUCONAZOLE (1144 patients)
BACTRIM (1135 patients)
ACIPHEX (1129 patients)
BACLOFEN (1119 patients)
PEPCID (1117 patients)
AMITRIPTYLINE HCL (1108 patients)
FLONASE (1107 patients)
VELCADE (1105 patients)
TAXOTERE (1103 patients)
ALL OTHER THERAPEUTIC PRODUCTS (1093 patients)
ENALAPRIL MALEATE (1085 patients)
RAMIPRIL (1083 patients)
ULTRAM (1081 patients)
ACETYLSALICYLIC ACID (1080 patients)
LOVENOX (1080 patients)
ZYPREXA (1071 patients)
ACYCLOVIR (1071 patients)
KETEK (1070 patients)
VITAMINS (1062 patients)
CLARITIN (1057 patients)
TRICOR (1046 patients)
GILENYA (1045 patients)
ZITHROMAX (1042 patients)
VYTORIN (1041 patients)
METOPROLOL SUCCINATE (1038 patients)
PAROXETINE HCL (1037 patients)
MOTRIN (1036 patients)
DIANEAL (1021 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about NAUSEA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.